abstract: BACKGROUND: Endometriosis (EM) is a benign gynecologic disease predominantly found in @entity1 of reproductive age. However, its pathogenesis is still poorly understood. Our experiment was designed to establish a stable and reliable cultural environment for coculture of endometrium and peritoneum, so as to observe the adhesion/invasion ability of endometrium from @entity1 with or without EM. METHODS: Endometria of secretory phase and peritoneum were sampled from 6 @entity1 with endometriois during laparoscopy. Six with @entity43 or simple @entity42 were taken as control. We cocultured endometrium and peritoneum into four groups (endometrium from EM cultured with peritoneum from EM, endometrium from control cultured with peritoneum from control, endometrium from EM cultured with peritoneum from non-EM and the endometrium from control cultured with peritoneum from EM) to observe the adhesion/invasion process in gas-liquid surface culture and in-medium culture. Specimens were collected at 1 hour, 6 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days and 7 days for histology, immunofluorescence and immunohistochemical analysis on @entity10585 ( @entity10585 ) and @entity2282 . RESULTS: The gas-liquid surface culture was superior to in-medium culture for the maintenance of tissue morphology and survival of endometrium. @entity10585 immunoflurescence demonstrated no remarkable difference in adhesion process between @entity1 with and without EM. @entity2282 immunochemistry manifested frequent invasion of endometrial stromal cells from EM @entity1 into peritoneum of up to 3 days culture, while the endometriotic cells from non-EM @entity1 did not invade into peritoneum. CONCLUSIONS: Gas-liquid surface culture is a suitable model for observing the early events in EM lesion formation. Endometrium from @entity1 with EM showed increased invasion capacity during coculture, which might help to explain the etiology of @entity46 .

title: Morphological analysis on adhesion and invasion involved in XXXX with tissue culture.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian teratoma']

entities_list: @entity42 :: ('MESH:D010048', 'Disease') :: ['ovarian cyst']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

answer: @entity46 :: (MESH:D004715,Disease) :: ['endometriosis']


abstract: BACKGROUND: Infantile proximal @entity2057 ( @entity2057 ) is a common @entity74 . Approximately 90% - 95% cases of @entity2057 result from homozygous deletion of @entity11280 ( @entity11280 ) and 5% cases are caused by compound heterozygous mutation (a @entity11280 deletion on one allele and a subtle mutation on the other allele). METHODS: In this research, two unrelated @entity1 were clinically diagnosed according to the criteria of proximal @entity2057 . Genetic diagnosis was performed to detect the homozygous deletion of exon 7 of @entity11280 by PCR-restriction fragment length polymorphism (RFLP) and genomic sequencing. Multiplex ligation-dependent probe amplification (MLPA) analysis was carried out to measure copy numbers of @entity11280 , @entity23247 and @entity23997 ( @entity23997 ) in the @entity1 . Further sequencing of @entity11280 allele-specific PCR (AS-PCR) and @entity11280 clones were also performed to analyze the point mutation of @entity11280 gene. Additionally, the pedigree analysis of these two families was carried out to identify the transmission of the mutation. RESULTS: The inconsistent results using PCR-RFLP and genomic sequencing showed homozygous deletion of exon 7 of @entity11280 and heterozygous deletion accompanied with a suspicious mutation in @entity11280 gene, respectively. MLPA analysis of these two cases exhibited one @entity11280 copy deletion. One identical @entity72939 ( @entity72940 ) mutation was found in two cases by sequencing the @entity11280 clones, which confirmed that both cases were @entity2057 compound heterozygotes. One case showed partial conversion to form hybrid SMN ( @entity23247 I7/ @entity11280 E8) identified by clones sequencing and another case carrying 3 @entity23247 implied complete conversion from @entity11280 to @entity23247 . CONCLUSION: @entity72940 is more a disease-causing mutation than a polymorphism variation, and @entity1 with this mutation may have more severe phenotypes.

title: Compound heterozygous mutation in two unrelated cases of Chinese XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['autosomal recessive neuromuscular disorder']

entities_list: @entity23997 :: ('4671', 'Gene') :: ['NAIP', 'neuronal apoptosis inhibitor protein']

entities_list: @entity11280 :: ('6606', 'Gene') :: ['SMN1', 'survival motor neuron gene 1']

entities_list: @entity2057 :: ('MESH:D009133', 'Disease') :: ['spinal muscular atrophy', 'SMA']

entities_list: @entity72940 :: ('p|SUB|R|288|M', 'ProteinMutation') :: ['p.Arg288Met']

answer: @entity2057 :: (MESH:D009133,Disease) :: ['spinal muscular atrophy']


abstract: BACKGROUND: Infantile proximal @entity2057 ( @entity2057 ) is a common @entity74 . Approximately 90% - 95% cases of @entity2057 result from homozygous deletion of @entity11280 ( @entity11280 ) and 5% cases are caused by compound heterozygous mutation (a @entity11280 deletion on one allele and a subtle mutation on the other allele). METHODS: In this research, two unrelated @entity1 were clinically diagnosed according to the criteria of proximal @entity2057 . Genetic diagnosis was performed to detect the homozygous deletion of exon 7 of @entity11280 by PCR-restriction fragment length polymorphism (RFLP) and genomic sequencing. Multiplex ligation-dependent probe amplification (MLPA) analysis was carried out to measure copy numbers of @entity11280 , @entity23247 and @entity23997 ( @entity23997 ) in the @entity1 . Further sequencing of @entity11280 allele-specific PCR (AS-PCR) and @entity11280 clones were also performed to analyze the point mutation of @entity11280 gene. Additionally, the pedigree analysis of these two families was carried out to identify the transmission of the mutation. RESULTS: The inconsistent results using PCR-RFLP and genomic sequencing showed homozygous deletion of exon 7 of @entity11280 and heterozygous deletion accompanied with a suspicious mutation in @entity11280 gene, respectively. MLPA analysis of these two cases exhibited one @entity11280 copy deletion. One identical @entity72939 ( @entity72940 ) mutation was found in two cases by sequencing the @entity11280 clones, which confirmed that both cases were @entity2057 compound heterozygotes. One case showed partial conversion to form hybrid SMN ( @entity23247 I7/ @entity11280 E8) identified by clones sequencing and another case carrying 3 @entity23247 implied complete conversion from @entity11280 to @entity23247 . CONCLUSION: @entity72940 is more a disease-causing mutation than a polymorphism variation, and @entity1 with this mutation may have more severe phenotypes.

title: Compound heterozygous mutation in two unrelated cases of Chinese @entity2057 XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The cellular localization of a 24,000 (24K) mol wt protein was evaluated by monoclonal antibody immunocytochemistry in @entity3202 and persistent proliferative endometrium as well as in various forms of hyperplastic and neoplastic @entity1 endometria. 24K was chiefly located in the cytoplasm of ciliated cells and their precursor forms, clear cells. It was absent in @entity3202 , resting, and regressive forms of @entity1373 . Persistent proliferative endometria with a low degree of proliferation has occasional 24K immunostained cells, whereas those with active proliferation contained intense 24K immunostaining. A similar pattern characterized the active forms of @entity1373 . The immunostaining reaction decreased in adenomatous and @entity1412 as well as in well differentiated @entity420 . In poorly differentiated @entity189 , 24K protein was virtually absent. These findings suggest that 24K protein is @entity172 and ciliated cell related, and endometrial ciliogenesis and 24K protein are morphological and biochemical markers, respectively, of the estrogenic endometrial response. Their increase and decrease in hyperplastic and neoplastic endometria support the concept that early @entity1373 is highly sensitive to estrogenic stimulation, whereas with increasing architectural and cytologic atypia, the estrogenic response decreases as a reflection of growing cell populations that are independent of estrogenic influence. Immunostaining with 24K is not sensitive enough to discriminate @entity172 -independent cells of @entity1412 from those of early, well differentiated @entity420 .

title: The presence of an XXXX -regulated protein detected by monoclonal antibody in abnormal @entity1 endometrium.

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['cystic glandular hyperplasia', 'hyperplasia']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['atypical adenomatous hyperplasia']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']

answer: @entity172 :: (MESH:D004967,Chemical) :: ['estrogen']


abstract: The cellular localization of a 24,000 (24K) mol wt protein was evaluated by monoclonal antibody immunocytochemistry in @entity3202 and persistent proliferative endometrium as well as in various forms of hyperplastic and neoplastic @entity1 endometria. 24K was chiefly located in the cytoplasm of ciliated cells and their precursor forms, clear cells. It was absent in @entity3202 , resting, and regressive forms of @entity1373 . Persistent proliferative endometria with a low degree of proliferation has occasional 24K immunostained cells, whereas those with active proliferation contained intense 24K immunostaining. A similar pattern characterized the active forms of @entity1373 . The immunostaining reaction decreased in adenomatous and @entity1412 as well as in well differentiated @entity420 . In poorly differentiated @entity189 , 24K protein was virtually absent. These findings suggest that 24K protein is @entity172 and ciliated cell related, and endometrial ciliogenesis and 24K protein are morphological and biochemical markers, respectively, of the estrogenic endometrial response. Their increase and decrease in hyperplastic and neoplastic endometria support the concept that early @entity1373 is highly sensitive to estrogenic stimulation, whereas with increasing architectural and cytologic atypia, the estrogenic response decreases as a reflection of growing cell populations that are independent of estrogenic influence. Immunostaining with 24K is not sensitive enough to discriminate @entity172 -independent cells of @entity1412 from those of early, well differentiated @entity420 .

title: The presence of an @entity172 -regulated protein detected by monoclonal antibody in abnormal XXXX endometrium.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: We studied the effects of @entity36013 , an @entity16511 kinase inhibitor, on @entity2109 ( @entity2109 ) and @entity978 ( @entity978 ) in @entity1 tissues and cell cultures and in a @entity19 xenograft model of @entity706 . @entity31323 levels were assessed by RT-PCR and immunohistochemistry. They were aberrantly expressed in @entity2109 and @entity978 cell lines, and in lymph nodes from @entity1 with @entity2109 and @entity978 . Next, activation of the @entity16511 promoter was detected by reporter gene assays. The promoter activity of @entity16511 kinase was high in @entity2109 cell lines and the @entity16511 promoter contained a positive regulatory region between -74 and -104 from the transcription initiation site. @entity36013 -hQPA had antiproliferative effects in the @entity2109 and @entity978 cell lines studied; inhibited the phosphorylation of histone H3 and @entity995 proteins, and resulted in cells with > 4N DNA content. @entity36013 -hQPA induced caspase-dependent apoptosis of some cell lines, demonstrated by loss of mitochondrial membrane potential, activation of @entity8187 , followed by activation of @entity522 . This effect was accompanied by the inhibition of survivin expression. In vivo efficacy was determined in NOD/ @entity915 /yc(null) @entity19 implanted with the Ramos @entity1 @entity2109 cell line. @entity36013 had anti- @entity5 effects in this @entity19 xenograft model. There preclinical data suggest that the inhibition of @entity16511 kinase is a potentially useful therapeutic strategy in @entity2109 and @entity978 .

title: Effects of @entity36013 , a selective @entity16511 kinase inhibitor, on Burkitt's and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity2109 :: ('MESH:D002051', 'Disease') :: ['BL', "Burkitt's lymphoma"]

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', "Hodgkin's lymphoma"]

entities_list: @entity995 :: ('MESH:D012175', 'Disease') :: ['retinoblastoma']

answer: @entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's lymphomas']


abstract: We studied the effects of @entity36013 , an @entity16511 kinase inhibitor, on @entity2109 ( @entity2109 ) and @entity978 ( @entity978 ) in @entity1 tissues and cell cultures and in a @entity19 xenograft model of @entity706 . @entity31323 levels were assessed by RT-PCR and immunohistochemistry. They were aberrantly expressed in @entity2109 and @entity978 cell lines, and in lymph nodes from @entity1 with @entity2109 and @entity978 . Next, activation of the @entity16511 promoter was detected by reporter gene assays. The promoter activity of @entity16511 kinase was high in @entity2109 cell lines and the @entity16511 promoter contained a positive regulatory region between -74 and -104 from the transcription initiation site. @entity36013 -hQPA had antiproliferative effects in the @entity2109 and @entity978 cell lines studied; inhibited the phosphorylation of histone H3 and @entity995 proteins, and resulted in cells with > 4N DNA content. @entity36013 -hQPA induced caspase-dependent apoptosis of some cell lines, demonstrated by loss of mitochondrial membrane potential, activation of @entity8187 , followed by activation of @entity522 . This effect was accompanied by the inhibition of survivin expression. In vivo efficacy was determined in NOD/ @entity915 /yc(null) @entity19 implanted with the Ramos @entity1 @entity2109 cell line. @entity36013 had anti- @entity5 effects in this @entity19 xenograft model. There preclinical data suggest that the inhibition of @entity16511 kinase is a potentially useful therapeutic strategy in @entity2109 and @entity978 .

title: Effects of XXXX , a selective @entity16511 kinase inhibitor, on Burkitt's and @entity978 .

answer: @entity36013 :: (MESH:C520647,Chemical) :: ['AZD1152']


abstract: We studied the effects of @entity36013 , an @entity16511 kinase inhibitor, on @entity2109 ( @entity2109 ) and @entity978 ( @entity978 ) in @entity1 tissues and cell cultures and in a @entity19 xenograft model of @entity706 . @entity31323 levels were assessed by RT-PCR and immunohistochemistry. They were aberrantly expressed in @entity2109 and @entity978 cell lines, and in lymph nodes from @entity1 with @entity2109 and @entity978 . Next, activation of the @entity16511 promoter was detected by reporter gene assays. The promoter activity of @entity16511 kinase was high in @entity2109 cell lines and the @entity16511 promoter contained a positive regulatory region between -74 and -104 from the transcription initiation site. @entity36013 -hQPA had antiproliferative effects in the @entity2109 and @entity978 cell lines studied; inhibited the phosphorylation of histone H3 and @entity995 proteins, and resulted in cells with > 4N DNA content. @entity36013 -hQPA induced caspase-dependent apoptosis of some cell lines, demonstrated by loss of mitochondrial membrane potential, activation of @entity8187 , followed by activation of @entity522 . This effect was accompanied by the inhibition of survivin expression. In vivo efficacy was determined in NOD/ @entity915 /yc(null) @entity19 implanted with the Ramos @entity1 @entity2109 cell line. @entity36013 had anti- @entity5 effects in this @entity19 xenograft model. There preclinical data suggest that the inhibition of @entity16511 kinase is a potentially useful therapeutic strategy in @entity2109 and @entity978 .

title: Effects of @entity36013 , a selective XXXX kinase inhibitor, on Burkitt's and @entity978 .

answer: @entity16511 :: (9212,Gene) :: ['Aurora B']


abstract: Defects of the mitochondrial respiratory chain are associated with a diverse spectrum of clinical phenotypes, and may be caused by mutations in either the nuclear or the mitochondrial genome (mitochondrial DNA (mtDNA)). Isolated @entity9714 is the most common enzyme defect in @entity2383 , particularly in @entity1 in whom family history is often consistent with sporadic or autosomal recessive inheritance, implicating a nuclear genetic cause. In contrast, although a number of recurrent, pathogenic mtDNA mutations have been described, historically, these have been perceived as rare causes of paediatric @entity9714 . We reviewed the clinical and genetic findings in a large cohort of 109 paediatric @entity1 with isolated @entity9714 from 101 families. Pathogenic mtDNA mutations were found in 29 of 101 probands (29%), 21 in @entity23706 subunit genes and 8 in mtDNA tRNA genes. Nuclear gene defects were inferred in 38 of 101 (38%) probands based on cell hybrid studies, mtDNA sequencing or mutation analysis (nuclear gene mutations were identified in 22 probands). @entity8433 was the most common clinical presentation in both mtDNA and nuclear genetic defects. The median age at onset was higher in mtDNA @entity1 (12 months) than in @entity1 with a nuclear gene defect (3 months). However, considerable overlap existed, with onset varying from 0 to >60 months in both groups. Our findings confirm that pathogenic mtDNA mutations are a significant cause of @entity9714 in @entity1 . In the absence of parental consanguinity, we recommend whole mitochondrial genome sequencing as a key approach to elucidate the underlying molecular genetic abnormality.

title: Respiratory chain XXXX caused by mitochondrial DNA mutations.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity8433 :: ('MESH:D007888', 'Disease') :: ['Leigh or Leigh-like disease']

entities_list: @entity9714 :: ('MESH:C537475', 'Disease') :: ['complex I deficiency']

entities_list: @entity2383 :: ('MESH:D028361', 'Disease') :: ['mitochondrial disorders']

answer: @entity9714 :: (MESH:C537475,Disease) :: ['complex I deficiency']


abstract: CONTEXT: Inhaled @entity842 has shown evidence of efficacy in @entity19 models of @entity3458 ( @entity3458 ), case series of @entity1 with @entity5837 , and 2 small placebo-controlled trials for treatment of vaso-occlusive @entity158 crisis (VOC). OBJECTIVE: To determine whether inhaled @entity842 gas reduces the duration of @entity158 in @entity1 with @entity3458 who present to the emergency department or hospital for care. DESIGN, SETTING, AND @entity1 : Prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial for up to 72 hours of inhaled @entity842 gas vs inhaled @entity1568 placebo in 150 @entity1 presenting with VOC of @entity3458 at 11 centers between October 5, 2004, and December 22, 2008. Intervention Inhaled @entity842 gas vs inhaled @entity1568 placebo. MAIN OUTCOME MEASURES: The primary end point was the time to resolution of @entity158 , defined by (1) freedom from parenteral opioid use for 5 hours; (2) @entity158 relief as assessed by visual analog @entity158 scale scores of 6 cm or lower (on 0-10 scale); (3) ability to walk; and (4) @entity1 's and family's decision, with physician consensus, that the remaining @entity158 could be managed at home. RESULTS: There was no significant change in the primary end point between the @entity842 and placebo groups, with a median time to resolution of crisis of 73.0 hours (95% confidence interval [CI], 46.0-91.0) and 65.5 hours (95% CI, 48.1-84.0), respectively (P = .87). There were no significant differences in secondary outcome measures, including length of hospitalization, visual analog @entity158 scale scores, cumulative opioid usage, and rate of @entity5837 . Inhaled @entity842 was well tolerated, with no increase in serious adverse events. Increases in venous @entity3961 concentration confirmed adherence and randomization but did not exceed 5% in any study @entity1 . Significant increases in plasma @entity1507 occurred in the treatment group, but there were no observed increases in plasma or whole blood @entity3542 . CONCLUSION: Among @entity1 with @entity3458 hospitalized with VOC, the use of inhaled @entity842 compared with placebo did not improve time to crisis resolution. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00094887.

title: @entity842 for inhalation in the acute treatment of sickle cell XXXX crisis: a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'participant', 'patient', 'PARTICIPANTS']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['SCD', 'sickle cell disease']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity5837 :: ('MESH:D056586', 'Disease') :: ['acute chest syndrome']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['painful crisis', 'pain']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: CONTEXT: Inhaled @entity842 has shown evidence of efficacy in @entity19 models of @entity3458 ( @entity3458 ), case series of @entity1 with @entity5837 , and 2 small placebo-controlled trials for treatment of vaso-occlusive @entity158 crisis (VOC). OBJECTIVE: To determine whether inhaled @entity842 gas reduces the duration of @entity158 in @entity1 with @entity3458 who present to the emergency department or hospital for care. DESIGN, SETTING, AND @entity1 : Prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial for up to 72 hours of inhaled @entity842 gas vs inhaled @entity1568 placebo in 150 @entity1 presenting with VOC of @entity3458 at 11 centers between October 5, 2004, and December 22, 2008. Intervention Inhaled @entity842 gas vs inhaled @entity1568 placebo. MAIN OUTCOME MEASURES: The primary end point was the time to resolution of @entity158 , defined by (1) freedom from parenteral opioid use for 5 hours; (2) @entity158 relief as assessed by visual analog @entity158 scale scores of 6 cm or lower (on 0-10 scale); (3) ability to walk; and (4) @entity1 's and family's decision, with physician consensus, that the remaining @entity158 could be managed at home. RESULTS: There was no significant change in the primary end point between the @entity842 and placebo groups, with a median time to resolution of crisis of 73.0 hours (95% confidence interval [CI], 46.0-91.0) and 65.5 hours (95% CI, 48.1-84.0), respectively (P = .87). There were no significant differences in secondary outcome measures, including length of hospitalization, visual analog @entity158 scale scores, cumulative opioid usage, and rate of @entity5837 . Inhaled @entity842 was well tolerated, with no increase in serious adverse events. Increases in venous @entity3961 concentration confirmed adherence and randomization but did not exceed 5% in any study @entity1 . Significant increases in plasma @entity1507 occurred in the treatment group, but there were no observed increases in plasma or whole blood @entity3542 . CONCLUSION: Among @entity1 with @entity3458 hospitalized with VOC, the use of inhaled @entity842 compared with placebo did not improve time to crisis resolution. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00094887.

title: XXXX for inhalation in the acute treatment of sickle cell @entity158 crisis: a randomized controlled trial.

answer: @entity842 :: (MESH:D009569,Chemical) :: ['Nitric oxide']


abstract: Radiotherapy in @entity5 is studied in a randomized phase-III clinical multicenter trial comparing (A) postoperative irradiation (50 Gy) to (B) preoperative irradiation + postoperative saturation (25 Gy) to (C) preoperative irradiation alone (25 Gy). Postoperative irradiation is carried out, if the @entity1 exhibits a high risk (Dukes B, C). In preoperatively irradiated @entity1 operation takes place immediately after the last course, at least within 24 h. Fractioning is 2,5 Gy per session. Preoperative irradiation is tolerated well. It does not compromise surgery or increase the number of complications. In rectal resections a protective colostomy is not necessary. @entity86 (A) is burdened by 3 serious complications and a considerably higher amount of complaints. Whereas radical radiation procedures (A and B) lead to a drastical reduction of the local recurrence rate (A 5 of 86, B 4 of 97 @entity1 , that means about 1/7th of what could be expected), preoperative irradiation alone (C) has a lesser effect (10 of 96). Distant @entity3 rate remains uninfluenced by each of these procedures. Assuming that preoperative irradiation is able to inhibit intraoperative metastasing these data suggest that this form of @entity3 has no practical importance. Although the study is not closed there is a convincing improvement by the combined radical approach. As regards tolerability and practicability it should be done in the sandwich-technique by pre-and postoperative irradiation (B).

title: [Adjuvant radiotherapy in XXXX ].

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rectosigmoidal cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['Radical postoperative irradiation']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity5 :: (MESH:D009369,Disease) :: ['rectosigmoid cancers']


abstract: OBJECTIVE: To examine behavioral observations of affiliation (ie, warmth versus hostility) and control (ie, dominance versus submissiveness) and prior divorce as predictors of @entity729 ( @entity729 ) in older couples. In some but not all studies, marital disruption and low marital quality have been shown to confer risk of @entity453 ( @entity453 ). Inconsistencies might reflect limitations of self-reports of marital quality compared with behavioral observations. Also, aspects of marital quality related to @entity453 might differ for @entity1 and @entity1 . METHODS: Couples underwent computed tomography scans for @entity729 and marital assessments, including observations of laboratory-based disagreement. @entity1 were 154 couples (mean age, 63.5 years; mean length of marriage, 36.4 years) free of prior diagnosis of @entity453 . RESULTS: Controlling traditional risk factors, we found behavioral measures of affiliation (low warmth) accounted for 6.2% of variance in @entity729 for @entity1 , p < .01, but not for @entity1 . Controlling behavior (dominance) accounted for 6.0% of variance in @entity729 for @entity1 , p < .02, but not for @entity1 . Behavioral measures were related to self-reports of marital quality, but the latter were unrelated to @entity729 . History of divorce predicted @entity729 for @entity1 and @entity1 . CONCLUSIONS: History of divorce and behavioral--but not self-report--measures of marital quality were related to @entity453 , such that low warmth and high dominance conferred risk for @entity1 and @entity1 , respectively. Prior research might underestimate the role of marital quality in @entity453 by relying on global self-reports of this risk factor.

title: Affiliation and control during marital disagreement, history of divorce, and asymptomatic XXXX in older couples.

entities_list: @entity729 :: ('MESH:D061205', 'Disease') :: ['coronary artery calcification', 'CAC']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Participants', 'men']

answer: @entity729 :: (MESH:D061205,Disease) :: ['coronary artery calcification']


abstract: OBJECTIVES: Increased mortality from @entity565 , chronic @entity3617 and @entity2415 has previously been reported among workers in the @entity12957 ( @entity12958 ) industry. The objective of the present study was to evaluate the influence of specific exposure factors on mortality from @entity3885 ( @entity3885 ), using a newly revised job-exposure matrix. MATERIALS AND METHODS: 1687 long-term workers employed in 1913-2003 in the Norwegian @entity12958 industry were characterised with respect to cumulative exposure to @entity3674 , @entity3440 , @entity12958 particles and @entity12958 fibres. Standardised mortality ratios (SMRs) for underlying causes of death, 1951-2007, were calculated stratified by category of cumulative exposure, and Poisson regression analyses of @entity3885 were performed using cumulative exposure variables. RESULTS: An increased total mortality (SMR 1.1, 95% CI 1.0 to 1.2) and increased mortality from @entity5 , non-malignant @entity1576 and external factors, were observed. The SMR of @entity3885 was increased at the highest level of cumulative exposure to all investigated exposure factors. In the internal analyses, a twofold increased risk of @entity3885 was observed with increasing levels of cumulative exposure to @entity12958 particles. In a multivariate model, @entity12958 particles showed the most stable increased risk estimate when controlled for other exposure factors, among workers with less than 15 years of employment. Among workers with more than 15 years of employment, crystalline @entity3440 , primarily cristobalite, seemed to be the most important exposure factor. CONCLUSION: Exposure to @entity12958 and crystalline @entity3440 may contribute to @entity3885 development among @entity12958 industry workers in different time windows, and possibly through different mechanisms.

title: Mortality from non-malignant XXXX among workers in the Norwegian @entity12957 industry: associations with dust exposure.

entities_list: @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity12957 :: ('MESH:C022088', 'Chemical') :: ['silicon carbide']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['OLD', 'obstructive lung diseases']

entities_list: @entity2415 :: ('MESH:D004646', 'Disease') :: ['emphysema']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory diseases']

entities_list: @entity3440 :: ('MESH:D012822', 'Chemical') :: ['silica', 'cristobalite']

answer: @entity1576 :: (MESH:D012131,Disease) :: ['respiratory diseases']


abstract: OBJECTIVES: Increased mortality from @entity565 , chronic @entity3617 and @entity2415 has previously been reported among workers in the @entity12957 ( @entity12958 ) industry. The objective of the present study was to evaluate the influence of specific exposure factors on mortality from @entity3885 ( @entity3885 ), using a newly revised job-exposure matrix. MATERIALS AND METHODS: 1687 long-term workers employed in 1913-2003 in the Norwegian @entity12958 industry were characterised with respect to cumulative exposure to @entity3674 , @entity3440 , @entity12958 particles and @entity12958 fibres. Standardised mortality ratios (SMRs) for underlying causes of death, 1951-2007, were calculated stratified by category of cumulative exposure, and Poisson regression analyses of @entity3885 were performed using cumulative exposure variables. RESULTS: An increased total mortality (SMR 1.1, 95% CI 1.0 to 1.2) and increased mortality from @entity5 , non-malignant @entity1576 and external factors, were observed. The SMR of @entity3885 was increased at the highest level of cumulative exposure to all investigated exposure factors. In the internal analyses, a twofold increased risk of @entity3885 was observed with increasing levels of cumulative exposure to @entity12958 particles. In a multivariate model, @entity12958 particles showed the most stable increased risk estimate when controlled for other exposure factors, among workers with less than 15 years of employment. Among workers with more than 15 years of employment, crystalline @entity3440 , primarily cristobalite, seemed to be the most important exposure factor. CONCLUSION: Exposure to @entity12958 and crystalline @entity3440 may contribute to @entity3885 development among @entity12958 industry workers in different time windows, and possibly through different mechanisms.

title: Mortality from non-malignant @entity1576 among workers in the Norwegian XXXX industry: associations with dust exposure.

answer: @entity12957 :: (MESH:C022088,Chemical) :: ['silicon carbide']


abstract: This study compares the efficacy of a new @entity3079 (TP-IV) with @entity7634 -Collins solution for long-term (72 hr) hypothermic storage of @entity235 pancreas autografts. Four experimental recipient groups and their survival (30-day study period) results were as follows: Gr. I (n = 6) pancreatectomized controls, without autotransplant (X +/- SD = 5.83 +/- 3.06 days); Gr. II (n = 6) fresh nonpreserved autografts (X +/- SD = 23.83 +/- 10.12 days, 5 of 6 greater than 30 days); and Gr. III (n = 7) and Gr. IV (n = 5) receiving pancreas autografts stored at 4 degrees C for 72 hr in either @entity7634 -Collins or TP-IV, respectively (Gr. III, 13.85 +/- 9.04 days; Gr. IV, 21.2 +/- 12.37 days). The results appear to indicate that TP-IV is superior to @entity7634 -Collins solution for 72-hr hypothermic storage of pancreas grafts. In fact, survival in the TP-IV-presented group was comparable to that of fresh, non-preserved autografts.

title: Pancreas preservation with TP-IV: a XXXX .

entities_list: @entity3079 :: ('MESH:D002288', 'Disease') :: ['hyperosmolar colloid solution']

answer: @entity3079 :: (MESH:D002288,Disease) :: ['hyperosmolar colloid solution']


abstract: BACKGROUND: Karapandzic flaps consist of well-vascularized, sensate lip tissue but are generally restricted to reconstruction of defects comprising two-thirds of the lip or less to avoid @entity8556 . Reconstruction of larger defects usually involves advancement flaps that require significant cheek laxity or free tissue transfer. METHODS: The authors describe a modification of the Karapandzic lower lip reconstruction technique in which the flaps are extended by recruiting tissue from the perioral cheek, allowing reconstruction of @entity3306 , which would normally not be reconstructible using the standard technique. @entity531 are carefully dissected and preserved to ensure innervation and perfusion. RESULTS: Eight @entity1 underwent successful single-stage lower lip reconstruction with this technique. In three cases, bilateral extended Karapandzic flaps were used for total lower @entity3306 , and in five additional cases, unilateral extended Karapandzic flaps were combined with other local flaps for near-total defects. All @entity1 achieved oral competence and normal or near-normal mouth opening. One @entity1 developed a @entity1410 and one @entity1 developed a @entity292 that healed with conservative treatment. There were no other complications. CONCLUSIONS: Extended Karapandzic flaps can be used to reconstruct near-total or total lower @entity3306 with innervated, well-vascularized tissues that recreate the oral sphincter and restore oral competence. By extending conventional Karapandzic flaps with perioral cheek tissue, adequate length is gained to avoid @entity8556 . In addition, the color match of the reconstructed lip is superior to reconstructions relying on tissue transfer from distant sites.

title: Extended Karapandzic flaps for XXXX .

entities_list: @entity3306 :: ('MESH:D008047', 'Disease') :: ['lip defects', 'near-total and total lower lip defects']

entities_list: @entity8556 :: ('MESH:D008865', 'Disease') :: ['microstomia']

entities_list: @entity531 :: ('MESH:D013901', 'Disease') :: ['Neurovascular structures']

answer: @entity3306 :: (MESH:D008047,Disease) :: ['near-total and total lower lip defects']


abstract: Bioluminescent fungi are widely distributed on land and most belong to the class Basidomycetes. Light of about 530 nm wavelength maximum is emitted continuously. The molecular basis for the light-emitting process remains unclear. We investigated the characteristics of the bioluminescence using cultivated fruiting bodies of M. @entity11546 . Only fresh fruiting bodies exhibited long-lasting light emission; rapid decay of light emission was observed with frozen and freeze-dried samples. Freeze-dried samples can be stored at room temperature under dry conditions and may be useful for the isolation of @entity10051 . The light emission of the fresh fruiting bodies was maintained in various buffers at varying pH; it could be stopped with @entity10003 @entity598 buffer and could be recovered at pH 6. The isolation of @entity10051 from the fresh fruiting bodies might be possible by the control of buffer pH. The effect of temperature on the light emission of fruiting bodies indicated that bioluminescence in M. @entity11546 may involve enzymatic reaction(s). The solubilization of bioluminescent components from the fruiting bodies could not be achieved with various surfactants.

title: Bioluminescence characteristics of the fruiting body of Mycena XXXX .

entities_list: @entity11546 :: ('MESH:D014236', 'Chemical') :: ['chlorophos']

entities_list: @entity10051 :: ('CHEBI:25078', 'Chemical') :: ['luciferin']

entities_list: @entity598 :: ('CHEBI:47622', 'Chemical') :: ['acetate']

answer: @entity11546 :: (MESH:D014236,Chemical) :: ['chlorophos']


abstract: BACKGROUND: With the widespread implementation of screening programs internationally, there will be an increase in early stage cervical @entity5 cases. In response to this, the Ministry of Health in each country will need to plan strategies to provide care such as radical surgery or radiation for this potentially curable group of @entity1 . METHODS: The Gynaecologic Oncologists of Canada created a teaching module to intensively train a small number of locally identified gynecologists to perform radical hysterectomy and pelvic lymphadenectomy. The process was based on adult learning principles; it involved a Canadian gynecologic oncologist working in the low- or middle-resource country with the gynecologists and problem-solving local issues in health care delivery. RESULTS: The teaching process included a pretest and a posttest on the basis of the objectives of the module. There were 7 modules including preoperative evaluation of the @entity1 , cone biopsy, radical hysterectomy, pelvic lymphadenectomy, @entity1901 , @entity1317 , and follow-up after surgery. Each module was divided into background information, techniques, and complications. There were video clips imbedded in the modules. After the educational modules had been reviewed, the learners were walked through the surgical procedures repeatedly including a detailed assessment of performance after each case. @entity1 had the opportunity to provide feedback on the training program. The module was reviewed in Mongolia and implemented in Kenya. CONCLUSIONS: In low- and middle-resource countries where there is an urgent need to provide a curative surgical option for the management of early cervical @entity5 , a focused high-intensity curriculum delivered by a trained surgeon can translate into immediate change in clinical and surgical practice.

title: XXXX surgery in low- or middle-resource countries.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient', 'Participants']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['vascular injury']

entities_list: @entity1901 :: ('MESH:D014515', 'Disease') :: ['ureteric injury']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Teaching cervical cancer']


abstract: BACKGROUND: @entity4854 at admission has been associated to an adverse prognosis in @entity1 with @entity583 ( @entity583 ). However, its impact over the results of reperfusion therapies in @entity1 with STEMI is still a matter of controversy. AIM: to determine the impact of admission @entity4854 on hospital and long term mortality, according to the method of reper-fusion utilized in @entity1 with STEMI. MATERIAL AND METHODS: prospective registry of 1,634 consecutive @entity1 aged 60    12 years (77% male), from 3 participating hospitals in the Chilean Registry of @entity583 (GEMI). We evaluated demographic, clinical and laboratory variables, reperfusion method used, hospital and long term mortality. The impact of @entity4854 on hospital and long term mortality was evaluated by a logistic regression analysis and Cox risk, respectively, adjusted by Thrombolysis in @entity583 (TIMI) risk score. RESULTS: twenty four percent of @entity1 were @entity6 and in 45%, the @entity1188 was located on the anterior wall. The mean TIMI risk score was 3.2    2.4. @entity4854 at entry was associated to a greater hospital and long term mortality, independently of the reperfusion strategy utilized. Primary angioplasty was associated to a greater benefit, compared to thrombolysis among @entity1602 @entity1 with an odds ratio: 2.9, 95% confi dence intervals: 1.0-8.0 and a hazard ratio of 2.9, 95% confi dence intervals: 1.44-5.88, independently of a previous history of @entity6 and TIMI risk score. CONCLUSIONS: in @entity1 with STEMI, admission @entity4854 is associated with a worse prognosis which was significantly improved with primary angioplasty compared to thrombolysis, independently of the admission TIMI risk score.

title: [Admission XXXX and mortality of ST segment elevation @entity583 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics', 'diabetes mellitus']

entities_list: @entity1602 :: ('MESH:D006944', 'Disease') :: ['hyperglycemic']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['ST-segment elevation acute myocardial infarction', 'Myocardial Infarction', 'STE-MI']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia', 'Hyperglycemia']

answer: @entity4854 :: (MESH:D006943,Disease) :: ['hyperglycemia']


abstract: BACKGROUND: @entity4854 at admission has been associated to an adverse prognosis in @entity1 with @entity583 ( @entity583 ). However, its impact over the results of reperfusion therapies in @entity1 with STEMI is still a matter of controversy. AIM: to determine the impact of admission @entity4854 on hospital and long term mortality, according to the method of reper-fusion utilized in @entity1 with STEMI. MATERIAL AND METHODS: prospective registry of 1,634 consecutive @entity1 aged 60    12 years (77% male), from 3 participating hospitals in the Chilean Registry of @entity583 (GEMI). We evaluated demographic, clinical and laboratory variables, reperfusion method used, hospital and long term mortality. The impact of @entity4854 on hospital and long term mortality was evaluated by a logistic regression analysis and Cox risk, respectively, adjusted by Thrombolysis in @entity583 (TIMI) risk score. RESULTS: twenty four percent of @entity1 were @entity6 and in 45%, the @entity1188 was located on the anterior wall. The mean TIMI risk score was 3.2    2.4. @entity4854 at entry was associated to a greater hospital and long term mortality, independently of the reperfusion strategy utilized. Primary angioplasty was associated to a greater benefit, compared to thrombolysis among @entity1602 @entity1 with an odds ratio: 2.9, 95% confi dence intervals: 1.0-8.0 and a hazard ratio of 2.9, 95% confi dence intervals: 1.44-5.88, independently of a previous history of @entity6 and TIMI risk score. CONCLUSIONS: in @entity1 with STEMI, admission @entity4854 is associated with a worse prognosis which was significantly improved with primary angioplasty compared to thrombolysis, independently of the admission TIMI risk score.

title: [Admission @entity4854 and mortality of ST segment elevation XXXX ].

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: BACKGROUND: Several clinical trials have been conducted over a period of many years reporting the benefits of @entity8124 for @entity195 ( @entity195 ) @entity1 . REVIEW SUMMARY: Randomized, double-blind, placebo-controlled stud-ies of 3-6 months' duration have demonstrated significant benefits for 5mg/D and 10 mg/D of @entity8124 compared with placebo. The results include benefits for cognition, activities of daily living, and abnormal behaviors associated with @entity195 . The benefits are independently detectable by clinicians based upon direct @entity1 assessment with input from a caregiver. Populations studied include mild-to-moderate @entity195 @entity1 , moderate-to-severe @entity195 @entity1 , nursing home @entity1 , and outpatients. Open label studies that took place after the double-blind phase and 1-year double-blind, placebo-controlled trials demonstrated that benefits persist for more than a year. Adverse event (AE) profiles, generated in studies that used a 1-week forced dose titration, show a low incidence of primarily cholinegic AEs such as @entity390 and @entity294 . There are no significant laboratory AEs or drug interactions. Recent studies have assessed the benefits of @entity8124 inpatients with @entity1294 , mild @entity73 , and other @entity73 . CONCLUSIONS: @entity8124 benefits @entity195 @entity1 by improving, stabilizing, or retarding decline of the cognitive, functional, and possibly behavioral features of the disease. The duration of benefits is not known but extends beyond 1 year. The drug is safe and well tolerated.

title: Update on Alzheimer drugs ( XXXX ).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1294 :: ('MESH:D015140', 'Disease') :: ['ischemic vascular dementia']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'cognitive disorders']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', 'Alzheimer disease']

entities_list: @entity8124 :: ('MESH:C076946', 'Chemical') :: ['donepezil', 'Donepezil']

answer: @entity8124 :: (MESH:C076946,Chemical) :: ['donepezil']


abstract: Constipation in @entity1 is a common health problem affecting 0.7% to 29.6% @entity1 across the world. Exact etiology for developing symptoms is not clear in @entity1 and the majority is considered to have functional @entity1142 . Alteration of rectal and pelvic floor function through the brain-gut axis seems to play a crucial role in the etiology. The diagnosis is often a symptom-based clinical process. Recently developed Rome III diagnostic criteria looks promising, both in clinical and research fields. Laboratory investigations such as barium enema, colonoscopy, anorectal manometry and colonic transit studies are rarely indicated except in those who do not respond to standard management. Treatment of childhood @entity1142 involves several facets including education and demystification, toilet training, rational use of laxatives for disimpaction and maintenance and regular follow-up. Surgical options should be considered only when medical therapy fails in long standing @entity1142 . Since most of the management strategies of childhood @entity1142 are not evidence-based, high-quality randomized controlled trials are required to assess the efficacy of currently available or newly emerging therapeutic options. Contrary to the common belief that @entity1 outgrow @entity1142 as they grow up, a sizable percentage continue to have symptoms beyond puberty.

title: Constipation in XXXX : novel insight into epidemiology, pathophysiology and management.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: AIM: To evaluate the outcome of surgery and radiotherapy in the treatment of @entity1653 ( @entity1653 ). METHOD: A retrospective study of 66 consecutive cases treated with surgery for @entity1653 with a minimum follow-up of 4 years. Clinical and radiological information were compared before and after the following surgical approaches: frontotemporal craniotomy, frontotemporal craniotomy combined with orbitozygomatic resection and extended lateral orbitotomy alone. RESULTS: The median age at presentation was 46 years (range, 26-68 years) and the median follow-up after surgery was 102 months (range, 48-288 months). In total, 48 (73%) @entity1 showed preoperative @entity227 , with @entity227 . All @entity1 had @entity5768 at presentation (mean    SD=6.4    3.0 mm). Surgery for @entity1 with @entity227 in 61% and improved vision in 30% of cases. Furthermore, a @entity5768 was achieved in 85% of @entity1 . The @entity5768 in this group was reduced by 2.6    2.6 mm. There was no correlation between surgical approach and @entity5768 reduction (p = 0.125). The recurrence rate was 17%. Only 1 out of 15 @entity1 who underwent radiotherapy showed signs of recurrence. CONCLUSIONS: The surgical aims in the treatment of @entity1653 should be the restoration of visual acuity and @entity5768 , @entity5 removal. The surgical approach can be tailored to individual cases. The authors recommend radiotherapy in cases of subtotally removed @entity1653 .

title: Surgical treatment of XXXX .

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['SOM arrested visual deterioration', 'visual deterioration', 'visual field defects']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['rather than complete tumour']

entities_list: @entity5768 :: ('MESH:D005094', 'Disease') :: ['substantial reduction of proptosis', 'proptosis', 'reduction of proptosis']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['SOM', 'sphenoorbital meningioma']

answer: @entity1653 :: (MESH:D008579,Disease) :: ['sphenoorbital meningiomas']


abstract: BACKGROUND: The safety and efficacy of upfront @entity2240 , before nephrectomy in metastatic clear cell @entity703 (mCRC), has not been prospectively evaluated. METHODS: Two prospective single-arm phase II studies investigated either two cycles (study A: n = 19) or three cycles (study B: n = 33) of @entity2240 before nephrectomy in mCRC. RESULTS: Overall, 38 of 52 (73%) of @entity1 obtained clinical benefit (by RECIST) before surgery. The partial response rate of the primary @entity5 was 6% [median reduction in longest diameter of 12% (range 8%-35%)]. No @entity1 became ineligible due to local progression of disease. A nephrectomy was carried out in 37 (71%) of @entity1 . Necrosis (>50%) was a prominent feature at nephrectomy in 49%. @entity532 (Clavien-Dindo classification) occurred in 10 (27%) @entity1 , including one @entity204 (3%). The median @entity190 and surgical time were 725 (90-4200) ml and 189 (70-420) min, respectively. The median progression-free survival was 8 months (95% confidence interval 6-15 months). A comparison of two versus three pre-surgery cycles showed no significant difference in terms of surgical complications or efficacy. CONCLUSIONS: Nephrectomy after upfront @entity2240 can be carried out safely. It obtains control of disease. Randomised studies are required to address if this approach is beneficial.

title: The safety and efficacy of XXXX before planned nephrectomy in metastatic clear cell @entity703 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['Surgical complications']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['renal cancer']

answer: @entity2240 :: (MESH:C473478,Chemical) :: ['sunitinib']


abstract: BACKGROUND: The safety and efficacy of upfront @entity2240 , before nephrectomy in metastatic clear cell @entity703 (mCRC), has not been prospectively evaluated. METHODS: Two prospective single-arm phase II studies investigated either two cycles (study A: n = 19) or three cycles (study B: n = 33) of @entity2240 before nephrectomy in mCRC. RESULTS: Overall, 38 of 52 (73%) of @entity1 obtained clinical benefit (by RECIST) before surgery. The partial response rate of the primary @entity5 was 6% [median reduction in longest diameter of 12% (range 8%-35%)]. No @entity1 became ineligible due to local progression of disease. A nephrectomy was carried out in 37 (71%) of @entity1 . Necrosis (>50%) was a prominent feature at nephrectomy in 49%. @entity532 (Clavien-Dindo classification) occurred in 10 (27%) @entity1 , including one @entity204 (3%). The median @entity190 and surgical time were 725 (90-4200) ml and 189 (70-420) min, respectively. The median progression-free survival was 8 months (95% confidence interval 6-15 months). A comparison of two versus three pre-surgery cycles showed no significant difference in terms of surgical complications or efficacy. CONCLUSIONS: Nephrectomy after upfront @entity2240 can be carried out safely. It obtains control of disease. Randomised studies are required to address if this approach is beneficial.

title: The safety and efficacy of @entity2240 before planned nephrectomy in metastatic clear cell XXXX .

answer: @entity703 :: (MESH:D007680,Disease) :: ['renal cancer']


abstract: OBJECTIVE: To determine the effectiveness of a serial screening program in achieving early detection and preventing @entity204 in @entity1 at increased risk for @entity320 . DESIGN: Retrospective study. SETTING: Private dermatology practice. @entity1 : The study included all @entity1 at increased risk for @entity320 who were screened in the program during the 17-year period, July 1, 1992-June 30, 2009 (=1108 @entity1 per year). MAIN OUTCOME MEASURES: Survival and indicators of early detection. RESULTS: All @entity320 that developed in program @entity1 during the 17-year period were detected early and there were no deaths, metastases, recurrences, nor need for sentinel node biopsies. An analysis of @entity320 cases seen in five recent years revealed additional evidence of consistent early detection: 80 percent of the lesions were in situ, no lesions were greater than 0.15 mm in @entity92 , and all lesions were in the radial growth phase, a stage almost always associated with cure. Four measures, often absent in mass screening programs, contributed to very early detection and cure: thorough serial examinations, biopsying suspicious lesions (particularly pigmented lesions that were highly irregular and/or approaching black in color), recalling @entity1 every six months to detect all @entity320 in the radial growth phase, and educating @entity1 on the need to return. CONCLUSION: An office-based surveillance program that includes serial full skin examinations and ongoing recalls appears capable of detecting @entity320 at a very early stage when cures can be realized in almost every case. Therefore, when @entity1 present with recognized risk factors for @entity320 , dermatologists should seriously consider recommending and performing such serial screening procedures.

title: Serial screening for XXXX : measures and strategies that have consistently achieved early detection and cure.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'PATIENTS']

entities_list: @entity92 :: ('MESH:D007222', 'Disease') :: ['Breslow depth']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'melanomas']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']


abstract: OBJECTIVES: To evaluate the locally-adapted CDSMP for older adults with @entity102 in Hong Kong in the primary care setting. DESIGN: A longitudinal, quasi-experimental study. SETTING: Community-based and primary care setting. @entity1 : Seven hundred and seventy-two @entity1 aged 55 or above with at least one @entity102 and were living in the community. INTERVENTION: The 6-weeks programme consisted of 6 group sessions, with each session lasting for 2.5 hours. Trained professional and elder lay leaders facilitated @entity1 to gain essential self-management knowledge and skills for the effective management of @entity102 . MEASUREMENTS: At baseline and 6 months, four categories of outcome measures were documented, covering self-management behaviours, self-efficacy, health status, and health care utilization. RESULTS: 302 and 298 @entity1 in the intervention and control groups completed 6 months follow-up respectively. @entity1 in the intervention group reported significant improvements in all self-management behaviours and self-efficacy measures, and 5 health status measures (social role limitation, @entity308 , health distress, symptoms of @entity158 and discomfort, and self-rated health) when compared with those in the control group. CONCLUSIONS: The locally-adapted CDSMP may improve self-management behaviours, self-efficacy and health status among older adults with @entity102 in Hong Kong. CDSMP may be integrated into primary care services for older adults.

title: Evaluation of XXXX self-management programme (CDSMP) for older adults in Hong Kong.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'PARTICIPANTS']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease', 'chronic diseases']

answer: @entity102 :: (MESH:D002908,Disease) :: ['chronic disease']


abstract: The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is widely involved in cell migration, apoptosis and @entity32 . However, its exact mechanisms in @entity656 ( @entity656 ) remain unclear. The aim of this study was to explore the activity of the JAK/STAT signaling pathway in @entity660 , investigate the functional mechanisms of @entity656 in  vitro, and thus elucidate the underlying therapeutic effects for @entity656 in  vivo. The activation of the @entity35709 / @entity30235 signaling pathway and the expessions of @entity1505 , @entity3426 and @entity568 proteins were investigated in AR42J cells induced with @entity8629 and treated with either PBS, RPM, or @entity22943 . One group of cells was left untreated as a control group. Subsequently the activity of @entity4026 was evaluated. @entity35 were given RPM or @entity22943 just before the induction of @entity656 , the severity of which was assessed at 24 h. The findings revealed that the up-regulated expressions of @entity35709 / @entity30235 , @entity12001 protein were closely correlated with the transcription of @entity1505 , @entity3426 , and @entity568 in @entity8629 -stimulated cells. Administration of RPM or @entity22943 decreased the activity of @entity4026 and inhibited the release of @entity1505 , @entity3426 , and @entity568 . The reflective markers of severity of @entity656 were also decreased by RPM or @entity22943 treatment compared to @entity656 @entity35 . This study indicates that the @entity35709 / @entity30235 signaling pathway activity is an early event in pancreatic @entity130 . Therefore, early treatment with its inhibitors might be beneficial for attenuation of @entity660 in @entity656 .

title: The antagonist of the @entity35709 / @entity30235 signaling pathway improves the severity of @entity8629 -stimulated XXXX via inhibition of @entity4026 activity.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity656 :: ('MESH:D019283', 'Disease') :: ['SAP', 'severe acute pancreatitis']

entities_list: @entity660 :: ('MESH:D010182', 'Disease') :: ['pancreatic injury']

entities_list: @entity8629 :: ('MESH:D002108', 'Chemical') :: ['cerulein']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['inflammatory injury']

answer: @entity660 :: (MESH:D010182,Disease) :: ['pancreatic injury']


abstract: The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is widely involved in cell migration, apoptosis and @entity32 . However, its exact mechanisms in @entity656 ( @entity656 ) remain unclear. The aim of this study was to explore the activity of the JAK/STAT signaling pathway in @entity660 , investigate the functional mechanisms of @entity656 in  vitro, and thus elucidate the underlying therapeutic effects for @entity656 in  vivo. The activation of the @entity35709 / @entity30235 signaling pathway and the expessions of @entity1505 , @entity3426 and @entity568 proteins were investigated in AR42J cells induced with @entity8629 and treated with either PBS, RPM, or @entity22943 . One group of cells was left untreated as a control group. Subsequently the activity of @entity4026 was evaluated. @entity35 were given RPM or @entity22943 just before the induction of @entity656 , the severity of which was assessed at 24 h. The findings revealed that the up-regulated expressions of @entity35709 / @entity30235 , @entity12001 protein were closely correlated with the transcription of @entity1505 , @entity3426 , and @entity568 in @entity8629 -stimulated cells. Administration of RPM or @entity22943 decreased the activity of @entity4026 and inhibited the release of @entity1505 , @entity3426 , and @entity568 . The reflective markers of severity of @entity656 were also decreased by RPM or @entity22943 treatment compared to @entity656 @entity35 . This study indicates that the @entity35709 / @entity30235 signaling pathway activity is an early event in pancreatic @entity130 . Therefore, early treatment with its inhibitors might be beneficial for attenuation of @entity660 in @entity656 .

title: The antagonist of the @entity35709 / XXXX signaling pathway improves the severity of @entity8629 -stimulated @entity660 via inhibition of @entity4026 activity.

answer: @entity30235 :: (25124(Tax:10116),Gene) :: ['STAT-1']


abstract: The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is widely involved in cell migration, apoptosis and @entity32 . However, its exact mechanisms in @entity656 ( @entity656 ) remain unclear. The aim of this study was to explore the activity of the JAK/STAT signaling pathway in @entity660 , investigate the functional mechanisms of @entity656 in  vitro, and thus elucidate the underlying therapeutic effects for @entity656 in  vivo. The activation of the @entity35709 / @entity30235 signaling pathway and the expessions of @entity1505 , @entity3426 and @entity568 proteins were investigated in AR42J cells induced with @entity8629 and treated with either PBS, RPM, or @entity22943 . One group of cells was left untreated as a control group. Subsequently the activity of @entity4026 was evaluated. @entity35 were given RPM or @entity22943 just before the induction of @entity656 , the severity of which was assessed at 24 h. The findings revealed that the up-regulated expressions of @entity35709 / @entity30235 , @entity12001 protein were closely correlated with the transcription of @entity1505 , @entity3426 , and @entity568 in @entity8629 -stimulated cells. Administration of RPM or @entity22943 decreased the activity of @entity4026 and inhibited the release of @entity1505 , @entity3426 , and @entity568 . The reflective markers of severity of @entity656 were also decreased by RPM or @entity22943 treatment compared to @entity656 @entity35 . This study indicates that the @entity35709 / @entity30235 signaling pathway activity is an early event in pancreatic @entity130 . Therefore, early treatment with its inhibitors might be beneficial for attenuation of @entity660 in @entity656 .

title: The antagonist of the @entity35709 / @entity30235 signaling pathway improves the severity of XXXX -stimulated @entity660 via inhibition of @entity4026 activity.

answer: @entity8629 :: (MESH:D002108,Chemical) :: ['cerulein']


abstract: The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is widely involved in cell migration, apoptosis and @entity32 . However, its exact mechanisms in @entity656 ( @entity656 ) remain unclear. The aim of this study was to explore the activity of the JAK/STAT signaling pathway in @entity660 , investigate the functional mechanisms of @entity656 in  vitro, and thus elucidate the underlying therapeutic effects for @entity656 in  vivo. The activation of the @entity35709 / @entity30235 signaling pathway and the expessions of @entity1505 , @entity3426 and @entity568 proteins were investigated in AR42J cells induced with @entity8629 and treated with either PBS, RPM, or @entity22943 . One group of cells was left untreated as a control group. Subsequently the activity of @entity4026 was evaluated. @entity35 were given RPM or @entity22943 just before the induction of @entity656 , the severity of which was assessed at 24 h. The findings revealed that the up-regulated expressions of @entity35709 / @entity30235 , @entity12001 protein were closely correlated with the transcription of @entity1505 , @entity3426 , and @entity568 in @entity8629 -stimulated cells. Administration of RPM or @entity22943 decreased the activity of @entity4026 and inhibited the release of @entity1505 , @entity3426 , and @entity568 . The reflective markers of severity of @entity656 were also decreased by RPM or @entity22943 treatment compared to @entity656 @entity35 . This study indicates that the @entity35709 / @entity30235 signaling pathway activity is an early event in pancreatic @entity130 . Therefore, early treatment with its inhibitors might be beneficial for attenuation of @entity660 in @entity656 .

title: The antagonist of the @entity35709 / @entity30235 signaling pathway improves the severity of @entity8629 -stimulated @entity660 via inhibition of XXXX activity.

answer: @entity4026 :: (81736(Tax:10116),Gene) :: ['NF-kB']


abstract: The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway is widely involved in cell migration, apoptosis and @entity32 . However, its exact mechanisms in @entity656 ( @entity656 ) remain unclear. The aim of this study was to explore the activity of the JAK/STAT signaling pathway in @entity660 , investigate the functional mechanisms of @entity656 in  vitro, and thus elucidate the underlying therapeutic effects for @entity656 in  vivo. The activation of the @entity35709 / @entity30235 signaling pathway and the expessions of @entity1505 , @entity3426 and @entity568 proteins were investigated in AR42J cells induced with @entity8629 and treated with either PBS, RPM, or @entity22943 . One group of cells was left untreated as a control group. Subsequently the activity of @entity4026 was evaluated. @entity35 were given RPM or @entity22943 just before the induction of @entity656 , the severity of which was assessed at 24 h. The findings revealed that the up-regulated expressions of @entity35709 / @entity30235 , @entity12001 protein were closely correlated with the transcription of @entity1505 , @entity3426 , and @entity568 in @entity8629 -stimulated cells. Administration of RPM or @entity22943 decreased the activity of @entity4026 and inhibited the release of @entity1505 , @entity3426 , and @entity568 . The reflective markers of severity of @entity656 were also decreased by RPM or @entity22943 treatment compared to @entity656 @entity35 . This study indicates that the @entity35709 / @entity30235 signaling pathway activity is an early event in pancreatic @entity130 . Therefore, early treatment with its inhibitors might be beneficial for attenuation of @entity660 in @entity656 .

title: The antagonist of the XXXX / @entity30235 signaling pathway improves the severity of @entity8629 -stimulated @entity660 via inhibition of @entity4026 activity.

answer: @entity35709 :: (84598(Tax:10116),Gene) :: ['JAK-1']


abstract: @entity4261 of the bone is a chronic disease characterized by accelerated bone turnover with abnormal repair leading to expansion, @entity4512 . The disease is common in the West, but little if any information is available on its existence in the Arab world, including Saudi Arabia. We present four cases of Saudi @entity1 with @entity4261 with variable presentations. The first case, a 63-year-old @entity1 with a history of @entity3557 , presented with bone, shoulder and chest wall @entity158 and foci of uptake in the ribs and skull that were thought to be @entity3 , indicating the possibility of diagnostic difficulty in a @entity1 with history of @entity5 . Bone biopsy confirmed the diagnosis of @entity4261 . The second case was a 47-year-old asymptomatic @entity1 with an elevated alkaline phosphatase of 427 U/L, a common presentation but at an unusual age. Plain x-rays and bone scan confirmed the diagnosis. The third case was a 43-year-old @entity1 who presented with @entity393 and @entity626 , unusual presentations at a young age leading to a delay in diagnosis. The fourth case was a 45-year-old @entity1 who presented with @entity158 and normal biochemical values, including a normal alkaline phosphatase. Bone biopsy unexpectedly revealed features of @entity4261 , which evolved over time into a classical form. A common feature in all except the first case was the relatively young age. @entity4261 does exist in Saudi Arabia, and it should be considered in the differential diagnosis of similar cases.

title: XXXX of the bone: does it exist in Saudi Arabia?

entities_list: @entity4512 :: ('MESH:D059352', 'Disease') :: ['pain and deformities']

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient', 'man']

entities_list: @entity3557 :: ('MESH:C536915', 'Disease') :: ['papillary thyroid cancer']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['right knee osteoarthritis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

entities_list: @entity4261 :: ('MESH:D010001', 'Disease') :: ['Paget disease']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'sacroiliac pain']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing impairment']

answer: @entity4261 :: (MESH:D010001,Disease) :: ['Paget disease']


abstract: BACKGROUND AND IMPORTANCE: @entity5642 is a relatively common complication in @entity1 with @entity130 , @entity295 , obstetric calamities, and certain @entity5 . We report a rare case of DIC after embolization and surgery for a large @entity1653 . We also review the literature on @entity1003 during @entity1313 surgery as well as the diagnosis and treatment of this complication. CLINICAL PRESENTATION: A 62-year-old @entity1 presented with a 3-week history of @entity2026 , difficulty with handwriting, personality change, and right-sided weakness. Magnetic resonance imaging demonstrated a 6.3   5.4-cm multilobe and avidly enhancing mass within the left frontal region. The @entity1 underwent preoperative transcatheter Onyx embolization of the @entity5 , followed immediately by craniotomy for resection of the @entity5 . Surgery was complicated by @entity1003 leading to substantial @entity190 . The diagnosis of @entity5642 was established by intraoperative thromboelastography, after which the @entity1 was treated with replacement therapy, Amicar, and modest @entity551 . One year after surgery, the @entity1 had fully recovered and had no focal @entity51 . CONCLUSION: This case report adds to the few reported cases of @entity5642 as a complication of @entity1313 surgery. This @entity1 's successful outcome may be attributed to timely recognition of the condition and effective, prompt treatment.

title: @entity5642 during resection of a XXXX : case report.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancies']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity1003 :: ('MESH:D001778', 'Disease') :: ['coagulopathy']

entities_list: @entity5642 :: ('MESH:D004211', 'Disease') :: ['Disseminated intravascular coagulation', 'disseminated intravascular coagulation']

entities_list: @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

answer: @entity1653 :: (MESH:D008579,Disease) :: ['meningioma']


abstract: BACKGROUND AND IMPORTANCE: @entity5642 is a relatively common complication in @entity1 with @entity130 , @entity295 , obstetric calamities, and certain @entity5 . We report a rare case of DIC after embolization and surgery for a large @entity1653 . We also review the literature on @entity1003 during @entity1313 surgery as well as the diagnosis and treatment of this complication. CLINICAL PRESENTATION: A 62-year-old @entity1 presented with a 3-week history of @entity2026 , difficulty with handwriting, personality change, and right-sided weakness. Magnetic resonance imaging demonstrated a 6.3   5.4-cm multilobe and avidly enhancing mass within the left frontal region. The @entity1 underwent preoperative transcatheter Onyx embolization of the @entity5 , followed immediately by craniotomy for resection of the @entity5 . Surgery was complicated by @entity1003 leading to substantial @entity190 . The diagnosis of @entity5642 was established by intraoperative thromboelastography, after which the @entity1 was treated with replacement therapy, Amicar, and modest @entity551 . One year after surgery, the @entity1 had fully recovered and had no focal @entity51 . CONCLUSION: This case report adds to the few reported cases of @entity5642 as a complication of @entity1313 surgery. This @entity1 's successful outcome may be attributed to timely recognition of the condition and effective, prompt treatment.

title: XXXX during resection of a @entity1653 : case report.

answer: @entity5642 :: (MESH:D004211,Disease) :: ['Disseminated intravascular coagulation']


abstract: STUDY DESIGN: A prospective study of @entity1 who underwent multilevel balloon kyphoplasty at a single institute. OBJECTIVE: To examine and compare the safety and long-term radiographic and clinical effects of unilateral or bilateral balloon kyphoplasty to treat multilevel symptomatic @entity3814 . SUMMARY OF BACKGROUND DATA: Typically, balloon kyphoplasty involves placement of inflatable bone tamp via a bilateral transpedicular or extrapedicular approach. Recently, several articles reported unilateral kyphoplasty with comparable outcomes. However, few prospective randomized study comparing the radiographic and clinical outcomes using unilateral and bilateral approaches was reported. METHODS.: Forty-nine @entity1 with 114 Osteoporotic @entity3814 were randomly allocated into two groups adopting unilateral or bilateral balloon kyphoplasty. @entity282 , and 36-Item Short Form Health Survey scores were compared with at least a 2-year follow-up. Vertebral body height and vertebral body kyphotic angle from this cohort were analyzed before surgery, after surgery, and at final follow-up. RESULTS: Both unilateral and bilateral balloon kyphoplasty resulted in significant @entity615 improvement and remained unchanged at final follow-up. Quality of life assessment using 36-Item Short Form Health Survey recorded marked and significant improvements in all mean subscale scores except general health and social function. Regarding the @entity615 , and 36-Item Short Form Health Survey scores, no significant difference existed between two groups. Significant increases of anterior and middle vertebral heights were recorded for both groups after surgery and maintained for the period of follow-up. The mean correction of vertebral body kyphotic angle was about 7   in both groups. Asymptomatic cement extravasation occurred in six of 49 of @entity1 , and three @entity1 developed additional @entity174 at untreated levels during the period of follow-up. CONCLUSIONS: Both unilateral and bilateral kyphoplasty markedly improve symptom-related clinical effects of multilevel @entity3814 and result in significant vertebral height restoration and @entity1513 correction that remains stable for at least 2 years after treatment.

title: Unilateral versus bilateral balloon kyphoplasty for multilevel XXXX : a prospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity3814 :: ('MESH:D050815', 'Disease') :: ['vertebral compression fractures']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['pain reduction and back dysfunction', 'pain reduction, back dysfunction']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['Preoperative and postoperative pain scores, back disability']

answer: @entity3814 :: (MESH:D050815,Disease) :: ['osteoporotic vertebral compression fractures']


abstract: For @entity1 erectile function is essential for quality of life. Besides urine incontinence postsurgical @entity323 ( @entity323 ) following radical prostatectomy (RPE) represents a significant and prevalent problem. One of the first approaches to this condition should be a consultation performed by professionals in a rehabilitation clinic.A total of 149 @entity1 post RPE participated in this prospective study. All @entity1 were questioned about their understanding of postoperative surgical @entity323 after RPE and if affected they were asked about their own psychological burden as well as their knowledge of possible therapy options. The qualities of presurgical @entity1 information as well as the modules of information pertaining to @entity323 during the rehabilitation were evaluated. Of the @entity1 , 53% expressed that they experienced a considerable burden due to postsurgical @entity323 during their follow-up rehabilitation (AR group) and 70% of the @entity1 during oncological rehabilitation treatment (rehab group). @entity1 who were sexually more active prior to surgery suffered more from postsurgical @entity323 than their less active counterparts. A negative correlation between psychological burden and age was found in the AR group, which however was levelled in the rehab group. Particularly in older @entity1 the burden of @entity323 increases with more time elapsing after the operation. The medical information on @entity323 therapy options provided during the inpatient rehabilitation was considered to be essential by 60% of the @entity1 in the AR group and 48% of the @entity1 in the rehab group.Therapeutic possibilities for postsurgical @entity323 following RPE cannot always be given to @entity1 in the preoperative phase or during their stay in the hospital. Since however a large majority of @entity1 suffer from @entity323 following RPE a specialized inpatient urological rehabilitation is suited for a comprehensive consultation.

title: [Counselling for XXXX during inpatient rehabilitation after radical prostatectomy].

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'patients', 'patient', 'Men']

entities_list: @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction', 'postoperative ED', 'ED']

answer: @entity323 :: (MESH:D007172,Disease) :: ['erectile dysfunction']


abstract: Here we analyze the essential process of X-chromosome dosage compensation (DC) to elucidate mechanisms that control the assembly, genome-wide binding, and function of gene regulatory complexes that act over large chromosomal territories. We demonstrate that a subunit of @entity2199 MLL/COMPASS, a gene activation complex, acts within the DC complex ( @entity18040 ), a condensin complex, to target the @entity18040 to both X chromosomes of hermaphrodites for chromosome-wide reduction of gene expression. The @entity18040 binds to two categories of sites on X: rex (recruitment element on X) sites that recruit the @entity18040 in an autonomous, sequence-dependent manner, and dox (dependent on X) sites that reside primarily in promoters of expressed genes and bind the @entity18040 robustly only when attached to X. We find that DC mutations that abolish rex site binding greatly reduce dox site binding but do not eliminate it. Instead, binding is diminished to the low level observed at autosomal sites in wild-type animals. Changes in @entity18040 binding to these non-rex sites occur throughout development and correlate directly with transcriptional activity of adjacent genes. Moreover, autosomal @entity18040 binding is enhanced by rex site binding in cis in X-autosome fusion chromosomes. Thus, dox and autosomal sites have similar binding potential but are distinguished by linkage to rex sites. We propose a model for @entity18040 binding in which low-level @entity18040 binding at dox sites is dictated by intrinsic properties correlated with high transcriptional activity. Sex-specific @entity18040 recruitment to rex sites then enhances the magnitude of @entity18040 binding to dox sites in cis, which lack high affinity for the @entity18040 on their own. We also show that the @entity18040 balances X-chromosome gene expression between sexes by controlling transcription.

title: An MLL/COMPASS subunit functions in the XXXX dosage compensation complex to target X chromosomes for transcriptional regulation of gene expression.

entities_list: @entity2199 :: ('6239', 'Species') :: ['Caenorhabditis elegans']

answer: @entity2199 :: (6239,Species) :: ['C. elegans']


abstract: BACKGROUND AND OBJECTIVES: Recent studies suggest an overall association between @entity740 ( @entity740 ) and @entity2520 , but it is unknown whether this association is similar across various subpopulations. DESIGN, SETTING, @entity1 , _ MEASUREMENTS: This study was a cross-sectional analysis of 2001 to 2004 National Health and Nutrition Examination Survey data. @entity740 was defined as a urinary albumin-to- @entity1011 ratio >= 30 mg/g or estimated GFR of 15 to 59 ml/min per 1.73 m(2). Adjusted odds ratios were calculated using multivariable logistic regression with U.S. population-based weighting. RESULTS: These analyses included 6199 dentate adult @entity1 (aged 21 to 75 years) with periodontal exams. The estimated prevalences of moderate/severe @entity2520 and @entity740 were 5.3% and 10.6%, respectively. @entity2520 was associated with >2-fold higher risk of @entity740 that was moderately attenuated after adjustment for age, gender, race/ethnicity, @entity286 use, @entity101 , @entity6 , educational attainment, poverty index ratio, and dental care use. There were no statistically significant interactions between @entity2520 and race/ethnicity, educational attainment, or poverty status. Less-than-recommended dental care use was associated with @entity2520 and @entity740 and was increasingly prevalent among nonwhites, lower educational attainment, and lower poverty status. CONCLUSIONS: The association between @entity2520 and @entity740 is not significantly different among subgroups. However, because nonwhites, those with a lower educational level, and the poor less frequently report use of recommended dental care, the association between @entity2520 and kidney function over time may become stronger among these groups and warrants further investigation.

title: Vulnerable populations and the association between periodontal and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'PARTICIPANTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease', 'Periodontal disease']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity740 :: (MESH:D051436,Disease) :: ['chronic kidney disease']


abstract: BACKGROUND: @entity3027 is one of the central agents in immunotherapy for @entity1358 ( @entity1358 ). It acts by binding to the @entity13969 ( @entity13969 ). We previously reported that increased @entity5 expression of @entity29513 mRNA was associated with the metastatic potential and progression of @entity1358 , as well as with a poor response of metastatic @entity1358 to @entity3027 therapy. This study investigated the influence of serum @entity29513 in @entity1358 @entity1 . METHODS: We measured serum @entity29513 mRNA levels and quantified @entity13969 mRNA expression in paired @entity5 and non- @entity5 tissues from the surgical specimens of 66 consecutive @entity1358 @entity1 by the real-time reverse transcription polymerase chain reaction (RT-PCR). We also measured phosphorylated @entity584 (Ser-473) and phosphorylated-S6 ribosomal protein (Ser-235/236) proteins levels in paired @entity5 and non- @entity5 tissues of @entity1 with metastatic @entity1358 by Western blotting. RESULTS: The serum level of @entity29513 mRNA was not associated with its @entity5 tissue level. Serum @entity29513 mRNA was positively correlated with @entity5 size (P  <  0.05), but not with @entity5 grade, pT stage, @entity3 , microscopic vascular invasion, or serum @entity1851 . Serum levels of @entity29513 mRNA were significantly higher in @entity1 with a good response to @entity3027    @entity2857 than in those with a poor response (P  <  0.0001). Tumor tissue @entity29513 mRNA levels and phosphorylated-S6 ribosomal protein (Ser-235/236) levels were associated with metastatic potential (P  <  0.001 and P  <  0.01, respectively), and @entity1 with a low @entity29513 mRNA level and low phosphorylated @entity584 (Ser-473) protein level in the @entity5 showed a good response to @entity3027    @entity2857 ( @entity3027    Sor: CR-PR) (P  <  0.01 and P  <  0.05, respectively). Kaplan-Meier survival analysis showed that a higher serum @entity29513 mRNA level was associated with longer overall survival of treated @entity1 (P  <  0.05), while a higher @entity5 tissue @entity29513 mRNA level was related to shorter overall survival (P  <  0.01). CONCLUSIONS: Our findings suggest that a high serum level of @entity29513 mRNA may be a useful marker for predicting the response of metastatic @entity1358 to @entity3027    @entity2857 therapy.

title: Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose @entity2857 for metastatic XXXX .

entities_list: @entity13969 :: ('3454', 'Gene') :: ['IFN-alpha receptor', 'IFNAR']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumor']

entities_list: @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity3027 :: ('3439', 'Gene') :: ['IFN-alpha', 'Interferon (IFN) alpha', 'IFN-a']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['clear cell renal cell carcinoma']


abstract: BACKGROUND: @entity3027 is one of the central agents in immunotherapy for @entity1358 ( @entity1358 ). It acts by binding to the @entity13969 ( @entity13969 ). We previously reported that increased @entity5 expression of @entity29513 mRNA was associated with the metastatic potential and progression of @entity1358 , as well as with a poor response of metastatic @entity1358 to @entity3027 therapy. This study investigated the influence of serum @entity29513 in @entity1358 @entity1 . METHODS: We measured serum @entity29513 mRNA levels and quantified @entity13969 mRNA expression in paired @entity5 and non- @entity5 tissues from the surgical specimens of 66 consecutive @entity1358 @entity1 by the real-time reverse transcription polymerase chain reaction (RT-PCR). We also measured phosphorylated @entity584 (Ser-473) and phosphorylated-S6 ribosomal protein (Ser-235/236) proteins levels in paired @entity5 and non- @entity5 tissues of @entity1 with metastatic @entity1358 by Western blotting. RESULTS: The serum level of @entity29513 mRNA was not associated with its @entity5 tissue level. Serum @entity29513 mRNA was positively correlated with @entity5 size (P  <  0.05), but not with @entity5 grade, pT stage, @entity3 , microscopic vascular invasion, or serum @entity1851 . Serum levels of @entity29513 mRNA were significantly higher in @entity1 with a good response to @entity3027    @entity2857 than in those with a poor response (P  <  0.0001). Tumor tissue @entity29513 mRNA levels and phosphorylated-S6 ribosomal protein (Ser-235/236) levels were associated with metastatic potential (P  <  0.001 and P  <  0.01, respectively), and @entity1 with a low @entity29513 mRNA level and low phosphorylated @entity584 (Ser-473) protein level in the @entity5 showed a good response to @entity3027    @entity2857 ( @entity3027    Sor: CR-PR) (P  <  0.01 and P  <  0.05, respectively). Kaplan-Meier survival analysis showed that a higher serum @entity29513 mRNA level was associated with longer overall survival of treated @entity1 (P  <  0.05), while a higher @entity5 tissue @entity29513 mRNA level was related to shorter overall survival (P  <  0.01). CONCLUSIONS: Our findings suggest that a high serum level of @entity29513 mRNA may be a useful marker for predicting the response of metastatic @entity1358 to @entity3027    @entity2857 therapy.

title: Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose XXXX for metastatic @entity1358 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity2857 :: (MESH:C471405,Chemical) :: ['sorafenib']


abstract: The current use of allogeneic bone marrow transplantation in various @entity1503 is reviewed. Bone marrow transplantation (BMT) involves infusion of bone marrow from a suitable donor into a properly conditioned recipient. Most BMT is allogeneic, in which the donor is genetically dissimilar but shares some common tissue antigens with the recipient. Almost all @entity1 undergoing allogeneic BMT must be "prepared" with high-dose @entity786 to prevent graft rejection. Most @entity1 with @entity1583 also receive total body irradiation to eradicate malignant cells located in areas inaccessible to the systemic circulation. Bone marrow transplantation is the treatment of choice for severe @entity2150 . In @entity3052 , the best results are observed in young @entity1 undergoing BMT in first remission. In @entity981 , BMT is usually reserved for @entity1 in second or subsequent remission. Early results are promising in @entity1 with @entity1860 who receive BMT before the accelerated phase or blast crisis of this disease. Allogeneic BMT offers an opportunity for cure in some @entity1 with relapses of @entity978 or those with certain subtypes of @entity1893 . Other diseases for which BMT has been used include severe @entity3230 disease, @entity11807 , and @entity1582 . Complications of BMT include graft failure or rejection, acute and @entity2132 , and infectious complications; late complications, such as restrictive and @entity3885 , @entity231 , sterility, and secondary @entity5 , may also occur. Bone marrow transplantation has become an important treatment for many @entity1503 , but it will probably remain a treatment reserved for only a few highly specialized centers. If morbidity and mortality caused by transplant-related complications can be reduced, BMT may be offered to older @entity1 and those without HLA-identical sibling donors.

title: Allogeneic bone marrow transplantation in the treatment of XXXX .

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoblastic leukemia']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataracts']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anemia']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstructive pulmonary disease']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic diseases']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['chronic graft-versus-host disease']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematologic malignancy']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"]

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's disease"]

entities_list: @entity3230 :: ('MESH:C565469', 'Disease') :: ['combined immune deficiency']

entities_list: @entity1860 :: ('MESH:D015464', 'Disease') :: ['chronic myelogenous leukemia']

entities_list: @entity11807 :: ('MESH:D005199', 'Disease') :: ["Fanconi's anemia"]

answer: @entity1503 :: (MESH:D006402,Disease) :: ['hematologic diseases']


abstract: @entity291 @entity378 in the United States has proven costly to @entity291 producers as well as to government regulatory agencies. While in vivo responsiveness to mycobacterial antigens is the current standard for the diagnosis of @entity378 , in vitro assays are gaining acceptance, especially as ancillary or complementary tests. To evaluate in vitro indices of cellular sensitization, antigen-induced gamma interferon ( @entity12028 ), @entity842 (NO), and @entity5 necrosis factor alpha ( @entity17299 ) responses by blood mononuclear cells from @entity2497 -infected @entity291 were quantified and compared. Using an aerosol model of @entity281 , two doses of each of two strains of @entity2499 (95-1315 and HC-2045T) were used to induce a range of @entity12028 , NO, and @entity17299 responses. Infection-specific increases in NO, but not in @entity12028 or @entity17299 , were detected in nonstimulated cultures at 48 h, a finding that is indicative of nonspecific activation and spontaneous release of NO. The infective dose of @entity2499 organisms also influenced responses. At 34 days postinfection, @entity12028 , NO, and @entity17299 responses in antigen-stimulated cells from @entity291 receiving 10(5) CFU of @entity2499 organisms were greater than responses of cells from @entity291 infected with 10(3) CFU of @entity2499 organisms. The NO response, but not the @entity12028 and @entity17299 responses, was influenced by infective strains of @entity2499 . The @entity17299 , NO, and @entity12028 responses followed similar kinetics, with strong positive associations among the three readouts. Overall, these findings indicate that NO and @entity17299 , like @entity12028 , may prove useful as indices for the diagnosis of @entity291 @entity378 .

title: Diagnostic implications of antigen-induced gamma interferon, @entity842 , and @entity5 necrosis factor alpha production by peripheral blood mononuclear cells from @entity2497 -infected XXXX .

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']

entities_list: @entity291 :: ('9913', 'Species') :: ['cattle', 'bovine', 'Bovine']

entities_list: @entity2497 :: ('1765', 'Species') :: ['Mycobacterium bovis']

answer: @entity291 :: (9913,Species) :: ['cattle']


abstract: @entity291 @entity378 in the United States has proven costly to @entity291 producers as well as to government regulatory agencies. While in vivo responsiveness to mycobacterial antigens is the current standard for the diagnosis of @entity378 , in vitro assays are gaining acceptance, especially as ancillary or complementary tests. To evaluate in vitro indices of cellular sensitization, antigen-induced gamma interferon ( @entity12028 ), @entity842 (NO), and @entity5 necrosis factor alpha ( @entity17299 ) responses by blood mononuclear cells from @entity2497 -infected @entity291 were quantified and compared. Using an aerosol model of @entity281 , two doses of each of two strains of @entity2499 (95-1315 and HC-2045T) were used to induce a range of @entity12028 , NO, and @entity17299 responses. Infection-specific increases in NO, but not in @entity12028 or @entity17299 , were detected in nonstimulated cultures at 48 h, a finding that is indicative of nonspecific activation and spontaneous release of NO. The infective dose of @entity2499 organisms also influenced responses. At 34 days postinfection, @entity12028 , NO, and @entity17299 responses in antigen-stimulated cells from @entity291 receiving 10(5) CFU of @entity2499 organisms were greater than responses of cells from @entity291 infected with 10(3) CFU of @entity2499 organisms. The NO response, but not the @entity12028 and @entity17299 responses, was influenced by infective strains of @entity2499 . The @entity17299 , NO, and @entity12028 responses followed similar kinetics, with strong positive associations among the three readouts. Overall, these findings indicate that NO and @entity17299 , like @entity12028 , may prove useful as indices for the diagnosis of @entity291 @entity378 .

title: Diagnostic implications of antigen-induced gamma interferon, @entity842 , and @entity5 necrosis factor alpha production by peripheral blood mononuclear cells from XXXX -infected @entity291 .

answer: @entity2497 :: (1765,Species) :: ['Mycobacterium bovis']